APELLIS PHARMACEUTICALS ($APLS) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of $0.47 per share, beating estimates of -$0.39 by $0.86. The company also reported revenue of $199,910,000, missing estimates of $203,394,171 by $-3,484,171.
You can see Quiver Quantitative's $APLS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
APELLIS PHARMACEUTICALS Insider Trading Activity
APELLIS PHARMACEUTICALS insiders have traded $APLS stock on the open market 39 times in the past 6 months. Of those trades, 0 have been purchases and 39 have been sales.
Here’s a breakdown of recent trading of $APLS stock by insiders over the last 6 months:
- CEDRIC FRANCOIS (Chief Executive Officer) has made 0 purchases and 5 sales selling 270,560 shares for an estimated $7,332,531.
- TIMOTHY EUGENE SULLIVAN (Chief Financial Officer) has made 0 purchases and 6 sales selling 69,764 shares for an estimated $1,837,125.
- A. SINCLAIR DUNLOP has made 0 purchases and 2 sales selling 62,184 shares for an estimated $1,451,097.
- DAVID O. WATSON (General Counsel) has made 0 purchases and 8 sales selling 56,087 shares for an estimated $1,341,646.
- NUR NICHOLSON (Chief Technical Officer) has made 0 purchases and 3 sales selling 12,546 shares for an estimated $269,827.
- PASCAL DESCHATELETS (Chief Scientific Officer) has made 0 purchases and 3 sales selling 9,114 shares for an estimated $197,537.
- CAROLINE BAUMAL (Chief Medical Officer) has made 0 purchases and 3 sales selling 7,699 shares for an estimated $175,224.
- MARK JEFFREY DELONG (Chief Business & Strat Officer) has made 0 purchases and 4 sales selling 6,853 shares for an estimated $147,420.
- JAMES GEORGE CHOPAS (VP/Chief Accounting Officer) has made 0 purchases and 5 sales selling 4,400 shares for an estimated $98,621.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
APELLIS PHARMACEUTICALS Hedge Fund Activity
We have seen 142 institutional investors add shares of APELLIS PHARMACEUTICALS stock to their portfolio, and 175 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 7,666,764 shares (+inf%) to their portfolio in Q4 2025, for an estimated $192,589,111
- ECOR1 CAPITAL, LLC removed 3,447,156 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,592,558
- WELLINGTON MANAGEMENT GROUP LLP added 3,430,392 shares (+36.9%) to their portfolio in Q4 2025, for an estimated $86,171,447
- JENNISON ASSOCIATES LLC removed 2,843,756 shares (-65.4%) from their portfolio in Q4 2025, for an estimated $71,435,150
- AQR CAPITAL MANAGEMENT LLC removed 2,210,667 shares (-49.3%) from their portfolio in Q4 2025, for an estimated $55,531,955
- AMUNDI removed 1,462,957 shares (-97.9%) from their portfolio in Q4 2025, for an estimated $36,749,479
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,261,426 shares (+43.8%) to their portfolio in Q4 2025, for an estimated $31,687,021
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
APELLIS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $APLS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/13/2026
- Stifel issued a "Buy" rating on 12/19/2025
- JP Morgan issued a "Overweight" rating on 11/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/31/2025
- TD Cowen issued a "Buy" rating on 10/31/2025
- Citigroup issued a "Buy" rating on 10/31/2025
- Wells Fargo issued a "Overweight" rating on 10/15/2025
To track analyst ratings and price targets for APELLIS PHARMACEUTICALS, check out Quiver Quantitative's $APLS forecast page.
APELLIS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $APLS recently. We have seen 13 analysts offer price targets for $APLS in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Eliana Merle from Barclays set a target price of $24.0 on 01/28/2026
- Tazeen Ahmad from B of A Securities set a target price of $28.0 on 01/21/2026
- Derek Archila from Wells Fargo set a target price of $26.0 on 01/20/2026
- Joseph Stringer from Needham set a target price of $28.0 on 01/13/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $35.0 on 01/13/2026
- Annabel Samimy from Stifel set a target price of $48.0 on 12/19/2025
- Anupam Rama from JP Morgan set a target price of $36.0 on 11/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
